Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETAMINE HCL vs DIPRIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Noncompetitive NMDA receptor antagonist; blocks glutamate binding, and modulates opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Induction and maintenance of general anesthesia,Procedural sedation and analgesia,Treatment-resistant depression (off-label),Acute pain management (off-label)
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in intensive care units,Monitored anesthesia care (MAC) sedation,Treatment of refractory status epilepticus (off-label),Procedural sedation (off-label)
Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV or 10-30 mcg/kg/min IV infusion; Subanesthetic: 0.1-0.5 mg/kg IV; Analgesic: IM 2-4 mg/kg; Intranasal 1-3 mg/kg. Frequency: single doses or continuous infusion per clinical need.
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
Terminal elimination half-life: 2–4 hours (alpha: 10–15 min, beta: 2.5–4 hr); prolonged in hepatic impairment and with repeated dosing (up to 12–24 hr for active metabolite norketamine).
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Hepatic; primarily via CYP3A4 and CYP2B6 to norketamine (active metabolite), then further metabolized by CYP2B6 and CYP2A6.
Primarily hepatic conjugation to inactive metabolites (propofol glucuronide), with minor metabolism via CYP2B6 and CYP2C9 to 4-hydroxypropofol.
Renal: 90% as metabolites (norketamine, dehydronorketamine, hydroxylated derivatives) and 4% unchanged; biliary/fecal: 3%; minor pulmonary exhalation.
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
47% bound primarily to albumin and alpha-1-acid glycoprotein.
95-99% bound, primarily to albumin.
2–4 L/kg (large distribution due to high lipophilicity; deep tissue compartments).
2-10 L/kg (large Vd indicating extensive tissue distribution).
IM: 93%; intranasal: 45–50%; oral: 17–20% (extensive first-pass metabolism).
Intravenous: 100%; not available orally due to extensive first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment (e GFR >=30 m L/min). Severe renal impairment (e GFR <30 m L/min): use with caution; no specific dosing guidelines; consider reduced doses and monitor for prolonged effects.
No adjustment required; propofol is not significantly renally eliminated.
Child-Pugh A: no adjustment. Child-Pugh B: consider 50% dose reduction. Child-Pugh C: avoid use or use extreme caution with significant dose reduction (e.g., 75% reduction) and monitor closely.
No specific Child-Pugh based guidelines; use lower doses due to impaired clearance, especially in cirrhosis.
Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV bolus or 5-20 mcg/kg/min IV infusion; IM: 2-5 mg/kg; Intranasal: 1-3 mg/kg. For procedural sedation: IV 0.5-1 mg/kg over 2-3 minutes; additional doses 0.25-0.5 mg/kg as needed. Weight-based dosing per kg.
Induction: 2.5-3.5 mg/kg IV bolus; maintenance: 125-300 mcg/kg/min IV infusion. Not approved for ICU sedation in <16 years.
Elderly patients: start with lowest effective doses; typical induction dose 0.5-1 mg/kg IV; reduce maintenance infusion rates (e.g., 5-10 mcg/kg/min); monitor for increased sensitivity, cognitive impairment, and cardiovascular effects; consider dose reduction of 25-50% compared to younger adults.
Reduce induction dose to 1-1.5 mg/kg IV bolus and maintenance infusion to 20-50 mcg/kg/min IV due to increased sensitivity and decreased clearance.
None.
Propofol should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Patients should be continuously monitored for early signs of hypotension, bradycardia, apnea, airway obstruction, and oxygen desaturation. For sedation of intubated, mechanically ventilated patients in the ICU, propofol should be used with caution in patients with increased intracranial pressure or impaired cerebral circulation.
Emergence reactions (delirium, hallucinations) can occur; minimize with benzodiazepines.,Hemodynamic instability: increased heart rate and blood pressure (contraindicated in hypertension/aneurysm).,Potential for abuse and dependence; schedule III controlled substance.,Laryngospasm and respiratory depression, especially at higher doses.,Increased intracranial pressure and intraocular pressure.
Risk of hypotension and bradycardia, especially in elderly or hypovolemic patients,Respiratory depression and apnea requiring airway management,Propofol infusion syndrome (PRIS): metabolic acidosis, rhabdomyolysis, renal failure, cardiac failure, especially with prolonged high-dose infusions,Hypertriglyceridemia; monitor lipids with prolonged use,Risk of pancreatitis,Use with caution in patients with epilepsy; may increase seizure risk during withdrawal,May cause green discoloration of urine, hair, or nails
Hypersensitivity to ketamine or any component,Conditions where significant blood pressure elevation is hazardous (e.g., aneurysms, uncontrolled hypertension),Severe coronary artery disease,Increased intracranial pressure or intraocular pressure,Pregnancy (only if benefit outweighs risk)
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, egg products, soybeans, or soy products (due to lipid vehicle),Patients with severe lipid metabolism disorders (e.g., hyperlipidemia),Not recommended for general anesthesia in patients with increased intracranial pressure or impaired cerebral circulation unless benefits outweigh risks
No known food interactions. Avoid alcohol and grapefruit juice due to potential CYP3A4 inhibition affecting metabolism.
No specific food interactions; however, propofol emulsion contains soybean oil and egg lecithin, so avoid in patients with egg or soy allergies. The emulsion can be contaminated if bottle is reused; discard after single use. No dietary restrictions required for administration.
Fetal risk cannot be ruled out; animal studies show adverse effects at maternal toxic doses. Human data limited; avoid in first trimester unless benefits outweigh risks. Potential for fetal neurotoxicity in third trimester; use only if clearly needed.
Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third trimesters, propofol crosses the placenta and may cause neonatal respiratory depression and neurobehavioral depression. Risk of fetal acidosis and bradycardia. No major teratogenic effects reported in human studies, but limited data.
M/P ratio unknown; ketamine enters breast milk in low amounts. Limited data; monitor infant for sedation. Weigh benefits against potential risks.
Propofol is excreted into breast milk in low concentrations. M/P ratio not established. Due to low oral bioavailability, risk to infant is minimal. However, caution is advised due to potential CNS depression in neonates. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration.
No specific dose adjustments required for pregnancy; consider increased volume of distribution and clearance. Use lowest effective dose; titrate to desired effect with careful monitoring.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, particularly in the third trimester. No specific dose adjustment guidelines; clinical response and patient condition determine dosing. Reduced doses may be required due to increased sensitivity to propofol in pregnancy.
Ketamine produces dissociative anesthesia with preserved airway reflexes and spontaneous respiration. Onset is rapid (30 seconds IV, 5 minutes IM). Emergence reactions (hallucinations, delirium) can be mitigated with benzodiazepines. Contraindicated in patients with elevated intracranial or intraocular pressure, hypertension, and severe coronary artery disease. Use with caution in psychiatric disorders. Subanesthetic doses are used for treatment-resistant depression and acute pain.
DIPRIVAN (propofol) causes pain on injection, especially in small veins; pretreatment with lidocaine or use of a larger vein can mitigate. It is formulated as a lipid emulsion containing soybean oil and egg lecithin, thus contraindicated in patients with egg or soybean allergies. Propofol can cause profound hypotension and respiratory depression; ensure airway equipment and vasopressors are immediately available. The infusion syndrome (PRIS) is rare but lethal, characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure; avoid prolonged high-dose infusions (>5 mg/kg/hr for >48 hours).
You may experience vivid dreams or confusion as the medication wears off.,Do not drive or operate machinery for at least 24 hours after receiving ketamine.,Avoid alcohol and other sedatives for 24 hours following treatment.,Inform your doctor if you have a history of high blood pressure, glaucoma, or psychiatric illness.,This medication may cause changes in perception or feeling of detachment during administration.
You will be monitored continuously during and after administration due to risk of low blood pressure and slowed breathing.,You may feel a burning or stinging sensation at the injection site; inform your healthcare provider if it persists.,Do not drive or operate machinery for at least 24 hours after receiving propofol due to residual sedation.,Inform your medical team if you have allergies to eggs, soy, or sesame seeds.,Propofol is not intended for home use; it is only administered in a supervised medical setting.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"The combination of ketamine and diamorphine can lead to additive central nervous system (CNS) depression and respiratory depression, increasing the risk of hypoxia, sedation, and respiratory arrest. Ketamine, an NMDA receptor antagonist, enhances opioid-induced analgesia but also potentiates the adverse effects of diamorphine, including hypotension and bradycardia. Patients may experience profound sedation, confusion, and cardiovascular instability, particularly at higher doses or in opioid-naive individuals."
"Ketamine, an NMDA receptor antagonist, may inhibit cytochrome P450 3A4 (CYP3A4) activity, which is responsible for the 25-hydroxylation of cholecalciferol (vitamin D3) to calcidiol (25-hydroxyvitamin D). This inhibition can reduce the conversion of cholecalciferol to its active form, potentially leading to decreased vitamin D levels and impaired calcium homeostasis. Clinically, this may increase the risk of vitamin D deficiency, contributing to bone demineralization, hypocalcemia, or secondary hyperparathyroidism in patients receiving long-term or high-dose ketamine therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETAMINE HCL vs DIPRIVAN, answered by our medical review team.
KETAMINE HCL is a General Anesthetic that works by Noncompetitive NMDA receptor antagonist; blocks glutamate binding, and modulates opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.. DIPRIVAN is a General Anesthetic that works by Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETAMINE HCL and DIPRIVAN depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETAMINE HCL is: Induction: 1-2 mg/kg IV; Maintenance: 0.5-1 mg/kg IV or 10-30 mcg/kg/min IV infusion; Subanesthetic: 0.1-0.5 mg/kg IV; Analgesic: IM 2-4 mg/kg; Intranasal 1-3 mg/kg. Frequency: single doses or continuous infusion per clinical need.. The standard adult dose of DIPRIVAN is: Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETAMINE HCL and DIPRIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETAMINE HCL is classified as Category C. Fetal risk cannot be ruled out; animal studies show adverse effects at maternal toxic doses. Human data limited; avoid in first trimester unless benefits outweigh risks. Potential . DIPRIVAN is classified as Category C. Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.